Berlin – Frederik Gärtner and Jens Kretzschmann advised early-stage investor 42CAP on the sale of its stake in Vienna-based biotech startup Allcyte to UK-based pharma tech company Exscientia. Exscientia is establishing a European Union office in Vienna in connection with the purchase of Allcyte. Exscientia had just recently announced the closing of a $225 million Series D financing round, in which Exscientia raised capital from investors including SoftBank's Vision Fund 2 and funds managed by BlackRock and Mubadala Investment Co. Using AI-powered image analysis, Allcyte has developed a method to generate actionable insights into the functional activity of drugs and drug candidates directly in viable, primary tissue samples from human cancer patients at the single-cell level. This enables the company to empower physicians to treat cancer patients with the most promising drug at the right time, when traditional genetics-driven precision medicine fails to provide precise answers. It also enables pharmaceutical companies to select the most promising drug candidates for clinical development in the right patient populations to maximize clinical trial success rates and patient benefit. Allcyte started in 2017 as a spin-off from the Vienna-based CeMM Research Center for Molecular Medicine. The Allcyte shareholders were advised on the sale by BRANDL TALOS. The team consisted of Roman Rericha, Stephan Strass and Céline Dobnikar.
"It is fascinating to see how in modern cancer therapy the use of artificial intelligence in combination with biomedicine can help to directly determine the degree of efficacy of treatments and maximize them in this way," says Jens Kretzschmann. "We are very pleased to have been able to provide 42CAP with legal and tax advice on this transaction once again," adds Frederik Gärtner.
Frederik Gärtner and Jens Kretzschmann had already advised 42CAP on the investment in Allcyte in spring 2021.
Download Press Release
Team:
Dr. Frederik Gärtner (Corporate), Partner
Jens Kretzschmann (Tax), Partner
About us
YPOG stands for You + Partners of Gamechangers – forward-thinking legal and tax advice. Supporting companies that are focused on emerging technologies, YPOG embraces change as an opportunity to develop cutting-edge solutions. The YPOG team offers comprehensive expertise in the areas of Funds, Tax, Transactions, Corporate, Banking, Regulatory + Finance, IP/IT/Data Protection, Litigation, and Corporate Crime + Compliance + Investigations. YPOG is one of the leading law firms in Germany for venture capital, private equity, fund structuring, and the implementation of distributed ledger technology (DLT) in financial services. Both the firm and its partners are regularly recognized by renowned national and international publications such as JUVE, Best Lawyers, Chambers and Partners, Leaders League, and Legal 500. YPOG is home to more than 150 experienced attorneys, tax advisors and tax specialists as well as a notary, working across offices in Berlin, Hamburg, Cologne, and Munich.
Further information: www.ypog.law/en/ and www.linkedin.com/company/ypog
